-- Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX) reported its third-quarter 2019 adjusted earnings of $0.17 per share and GAAP loss of $0.03
Allscripts (NASDAQ: MDRX): Q3 2019 Earnings Snapshot
Categories
Health Care
Bausch Health beats Q3 estimates; raises full-year guidance
Bausch Health Companies Inc. (NYSE: BHC) beat revenue and earnings expectations for the third quarter of 2019, allowing the shares to gain
Allergan (AGN) Q3 earnings preview: Patent issues, AbbVie deal in focus
After securing shareholders' approval for the takeover deal with AbbVie (ABBV), Allergan (NYSE: AGN) will be publishing its third-quarter results on November
Immunogen Inc (NASDAQ:IMGN) Q3 2019 Earnings Call Transcript
Immunogen Inc (IMGN) Q3 2019 earnings call dated Nov 1, 2019 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor Relations
AbbVie (NYSE: ABBV) Q3 profit dips 31% but beats estimates
AbbVie Inc. (NYSE: ABBV) reported a 31% dip in earnings for the third quarter of 2019 due to higher costs and expenses.
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG): Q3 2019 Earnings Snapshot
-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) reported a net loss of $23.62 million or $0.70 per share for the third quarter of
Sanofi (NASDAQ: SNY): Q3 2019 Earnings Snapshot
-- Generic drugmaker Sanofi (NASDAQ: SNY) reported net income of EUR 1.77 billion or EUR 1.49 per share for the third quarter,
Celgene (CELG) Q3 profit jumps 56% beats estimates
Celgene Corporation (NASDAQ: CELG) reported a 56% jump in earnings for the third quarter of 2019 helped by higher revenue as well
Abiomed’s (ABMD) revenue increases 13% in Q2 on higher usage of Impella; reiterates 2020 outlook
Abiomed (NASDAQ: ABMD) reported a 13% growth in second quarter 2020 revenue, boosted by the increased usage of its Impella heart pumps.
Bristol-Myers Squibb (BMY) earnings: Q3 results beat amid strong product sales
Driven by the strong sales of leading products, earnings of Bristol-Myers Squibb (NYSE: BMY) increased in the third quarter and exceeded the
Cigna (NYSE: CI): Q3 2019 Earnings Snapshot
-- Cigna Corporation (NYSE: CI) reported its third-quarter 2019 adjusted operating earnings of $4.54 per share versus $4.36 per share expected. --
ACADIA Pharmaceuticals (ACAD): Q3 2019 Earnings Snapshot
-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q3 2019 loss of $0.29 per share, vs. $0.40 expected. -- Revenues grew 62% to
Vertex Pharmaceuticals (VRTX): Q3 2019 Earnings Snapshot
-- Vertex Pharmaceuticals (NASDAQ: VRTX) reported third-quarter 2019 earnings of $1.23 per share, vs. $1.15 per share expected -- Total revenue grew
Bristol-Myers (BMY) Q3 earnings preview: New indications, pipeline to bolster recovery
Bristol-Myers Squibb (NYSE: BMY) will be publishing its September-quarter earnings Thursday before the opening bell. The bio-pharmaceutical company is expected to earn
McKesson Corporation (MCK): Q3 2019 Earnings Snapshot
-- McKesson Corporation (NYSE: MCK) reported third-quarter 2019 earnings of $3.60 per share, in line with the street projection. -- Total revenue
Stryker (SYK): Q3 2019 Earnings Snapshot
-- Stryker (NYSE: SYK) reported third-quarter 2019 earnings of $1.91 per share, vs. $1.90 per share expected. -- Total revenue grew 10.6%
Amgen beats in Q3, raises guidance
Amgen Inc (NASDAQ: AMGN) reported third-quarter 2019 adjusted EPS of $3.66 on revenue of $5.74 billion. This was better than analysts’ prediction
Pfizer (PFE) reports better-than-expected Q3 results; stock gains
Drugmaker Pfizer (NYSE: PFE) reported lower revenues and earnings for the third quarter. The results, however, topped the market's expectations. The management
Merck’s (MRK) Q3 results beat estimates; sales boosted by oncology and vaccines
Merck (NYSE: MRK) surpassed analysts’ expectations for revenue and earnings in the third quarter of 2019, sending the shares climbing 2.5% in
Walgreens Boots (WBA) earnings preview: No surprises expected in Q4 report
It has been a tough year for Walgreens Boots Alliance (NASDAQ: WBA) so far, with the stock losing steadily amid muted sales
Gilead Sciences, Inc (GILD): Q3 2019 Earnings Snapshot
-- Gilead Sciences (NYSE: GILD) reported third-quarter 2019 earnings of $1.75 per share, vs. $1.74 per share expected. -- Total revenue remained